One phase II trial examining a combination therapy for R/M HNSCC using EGFR inhibition as well as PD-1 inhibition has also shown encouraging results, with a 45% overall response rate at 6 months with a relatively favorable side effect profile. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.